Bristol-Myers Drops Alzheimer’s Drug on Little Benefit

Bristol-Myers Squibb Co. ended development of an experimental Alzheimer’s disease treatment after the drug was shown not to be effective, the company said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.